ReviewMolecular medicine reports2026
Research progress of aptamers in the diagnosis and treatment of colorectal cancer (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer‑related deaths. The high incidence rate and poor prognosis of CRC pose a serious threat to public health, and impose a notable social and economic burden. Therefore, improving the accuracy of the early diagnosis and treatment of CRC is of notable importance. Aptamers have substantial potential for tumor‑targeted diagnosis and treatment due to their unique advantages, such as high affinity, high specificity and programmability. In the diagnosis and treatment of CRC, aptamers can specifically target receptors on the surface of cancer cells and intervene in the development of CRC by inhibiting receptor activity. The present study reviews the current state of research on aptamers to provide a new scientific basis and methods for diagnosing and treating CRC. The relevant research achievements are organized based on the two major branches of diagnostic detection and targeted therapy to systematically assess the translational value of various CRC aptamers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.